The global ulcerative colitis drug market is forecast to reach USD 10.69 Billion by 2028, according to a new report by Reports and Data. Ulcerative colitis (UC) can be defined as an inflammatory bowel disease, which is chronic in nature. Some of the mentionable symptoms associated with the condition is inflammation, irritation, and ulcers in the lining of the colon. The disease does not have a cure, and patients of the condition experience revival of the symptoms. However, with the help of the right treatment, the condition and associated signs symptoms can be effectively managed. The exact cause for the occurrence of the condition remains unknown. Previously stress and diet was suspected to be the cause for the occurrence of the disease. However, now it is known that stress and diet may aggravate the condition. Heredity and immune system malfunction are considered to be the possible cause for the occurrence of the disease. There are two main goals of UC treatment. The first is to control the symptom enhance the comfort of patients and increasing the healing of colon. The second aim is to avoid more flare-ups. The focus of the treatment is to minimize control the signs and symptoms of the disease. 

Market Overview:

The pharma and healthcare industry is at a crossroads. Patients are benefiting from the promise of cell and gene therapies; uncommon diseases that were previously thought to be incurable are on the verge of finding true treatments. Artificial intelligence (AI) and machine-learning technologies are creating hopes that therapy discovery and development would be more innovative, as well as faster and cheaper. Manufacturing, the supply chain, and the entire healthcare ecosystem all have the potential to benefit from data-driven initiatives. Consumer attitudes and behaviours are shifting in a variety of ways, from growing use of technology and willingness to share data to an interest in using tools to make prescription and treatment decisions. Such factors will drive pharma and healthcare market growth in the coming years.

Some key highlights of the report:

• The Ulcerative Colitis Drug market held a market share of USD 6.79 Billion in the year 2018 that is forecasted to grow at a rate of 4.6% during the forecast period.
• In context to Drug Type, the Biologics segment generated the highest revenue of USD 2.78 Billion in 2018, with a CAGR of 4.50% during the forecast period. The effectiveness of Biologics in working in a selective manner, rather than affecting the whole body that results in reducing medication-related side effects and elevated preference among care providers and care users contributes to the revenue generated by this segment.
• In context to Route of Administration, the Oral segment is projected to witness a faster growth rate of 5.4% during the forecast period. The growth rate witnessed by the segment is attributed to the presence of strong pipeline products and continuous developments in various drugs, along with rising awareness about the condition. Increasing awareness about the disease results in early detection of the condition and increasing demand for 5-aminosalicylic acid, which is usually the first step of treatment.
• In context to Distribution Channel, the Hospitals Pharmacy segment held the largest market share of 45.0% in 2018, with a CAGR of 4.7% during the forecast period. The market share occupied by the Hospitals Pharmacy segment is resultant of the rising incidence rate of the condition, increase in the number of in-patient and out-patients, elevation in the number of hospitalization associated with the disease, which results in high demand for medications of the disease from this distribution channel.
• In regards to Application, the Ulcerative proctitis segment generated the highest revenue of USD 3.80 Billion in 2018, with a CAGR of 5.1% during the forecast period. The high incidence rate of the condition results in high demand for UC drug in this segment.
• In regards to the region, Asia Pacific is projected to witness the fastest growth rate of 5.1% during the forecast, which is expected to hold 8% of the market by 2027. The growth rate witnessed by the region is resultant of changing lifestyle that triggers the number of patients affected by this condition along with expansion of the health care sector and rising product approvals, which are supporting the market growth in this region.

 Key Players covered in this report are

 Bausch Health Companies Inc. (Salix Pharmaceutical), AbbVie Inc., Johnson and Johnson, Boehringer Ingelheim GmbH, Novartis AG, Merck Co., Teva Pharmaceuticals Ltd., Takeda Pharmaceuticals, Shire, Pfizer Inc.

Drug Type Outlook (Revenue, USD Billion; 2018-2028)

• Biologics
• Corticosteroids
• Immunomodulators
• 5-aminosalicylic acid
• Immunosuppressant
• Biosimilars
• Others

Route of Administration Outlook (Revenue, USD Billion; 2018-2028)

• Oral
• Injectable

Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)

• Hospitals Pharmacy
• Online Pharmacy
• Retail Pharmacy

Application Outlook (Revenue, USD Billion; 2018-2028)

• Proctosigmoiditis
• Ulcerative proctitis
• Pancolitis
• Left-sided colitis
• Acute severe ulcerative colitis

Key Regional Markets Studied in the Report:

• North America (U.S., Canada)
• Europe (U.K., Italy, Germany, France, Rest of EU)
• Latin America (Chile, Brazil, Argentina, Rest of Latin America)
• Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
• The Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request a customization of the report @ https://www.reportsanddata.com/report-detail/ulcerative-colitis-drug-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.